Serum Protein Profile at Remission Can Accurately Assess Therapeutic Outcomes and Survival for Serous Ovarian Cancer

摘要: Background Biomarkers play critical roles in early detection, diagnosis and monitoring of therapeutic outcome recurrence cancer. Previous biomarker research on ovarian cancer (OC) has mostly focused the discovery validation diagnostic biomarkers. The primary purpose this study is to identify serum biomarkers for prognosis outcomes cancer. Experimental Design Forty proteins were analyzed 70 samples from healthy controls (HC) 101 serous OC patients at three different disease phases: post (PD), remission (RM) (RC). utility as was evaluated using a variety statistical methods including survival analysis. Results Ten (PDGF-AB/BB, PDGF-AA, CRP, sFas, CA125, SAA, sTNFRII, sIL-6R, IGFBP6 MDC) have individually good area-under-the-curve (AUC) values (AUC = 0.69–0.86) more than 10 three-marker combinations excellent AUC (0.91–0.93) distinguishing active (PD & RC) HC. mean protein levels RM are usually intermediate between HC with RC). Most importantly, five (sICAM1, RANTES, sgp130, sTNFR-II sVCAM1) measured can classify, combination, into two subsets significantly overall (best HR 17, p<10−3). Conclusion We identified which, when remission, accurately predict patients, suggesting that they may be useful